drugset
drugset / Trial / NCT04778059

Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19

NCT04778059 ↗

Phase 2 Terminated 21 enrolled US Biotest, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This trial will study the use of USB002 given as an intravenous infusion in patients with respiratory distress due to infection with COVID-19.

Timeline

Start
2021-07-27
Primary completion
2022-05-10
Completion
2022-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject talfirastide Peptide — Intravenous

Indications

COVID-19 adult acute respiratory distress syndrome